Literature DB >> 3782647

Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension.

V E Smith, W B White, M K Meeran, M K Karimeddini.   

Abstract

Abnormal left ventricular diastolic performance, an early manifestation of hypertension in the heart, may precede the development of left ventricular hypertrophy. To assess effects of antihypertensive therapy on the heart, left ventricular mass (determined by echocardiography) and rapid left ventricular filling rate (determined by radionuclide ventriculography) were compared before and after 6 months of treatment of 16 patients. Nitrendipine (a dihydropyridine calcium channel blocker) was given alone or in combination with either propranolol or hydrochlorothiazide, or both, and significantly reduced blood pressure (156/103 +/- 12/7 to 137/89 +/- 10/6 mm Hg). In 6 of the 16 patients, left ventricular mass decreased by more than 10% (270 +/- 95 to 193 +/- 47 g, p less than 0.01); in the same patients, left ventricular filling rate increased (2.03 +/- 0.35 to 2.30 +/- 0.45 end-diastolic counts/s [EDC/s], p less than 0.01). In the one patient whose left ventricular mass increased (137 to 195 g), left ventricular filling rate decreased from 2.01 to 1.78 EDC/s. In the remaining nine patients who had no change in left ventricular mass, there was no significant changes in left ventricular filling. The changes in ventricular mass and filling could not be related to the extent of change in blood pressure or heart rate. These data suggest that regression of left ventricular mass during antihypertensive therapy with nitrendipine is accompanied by improved diastolic function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782647     DOI: 10.1016/s0735-1097(86)80322-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.

Authors:  E Foster; J F Plehn; S A Bernard; N J Battinelli; M Huntington-Coats; C S Apstein
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Effects of different antihypertensive drugs on left ventricular function.

Authors:  R Oliveri
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Imaging in hypertensive heart disease.

Authors:  Rajesh Janardhanan; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-02

4.  Correlations of left ventricular diastolic parameters and heart rate: assessment through right ventricular pacing.

Authors:  Z X He; J Darcourt; J P Camous; J Benoliel; O Migneco; F Bussière-Lapalus; M Baudouy; P Morand
Journal:  Eur J Nucl Med       Date:  1992

5.  Left ventricular mass changes with nicardipine therapy in essential hypertension.

Authors:  P Gosse; P Lacroix; R Roudaut; M Dallocchio
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 6.  Diastolic function in hypertension.

Authors:  R A Phillips; J A Diamond
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

7.  Left ventricular hypertrophy regression during antihypertensive treatment.

Authors:  H Eichstaedt; O Danne; R J Schroeder; D Kreuz
Journal:  Clin Investig       Date:  1992

8.  Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy.

Authors:  F H Leenen; R J Burns; M G Myers; D Frankel
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 9.  Hypertension and diastolic function.

Authors:  E Agabiti-Rosei; M L Muiesan
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  The role of imaging in hypertensive heart disease.

Authors:  Edward T D Hoey; Vijayabhaskar Pakala; Jun K Teoh; Helen Simpson
Journal:  Int J Angiol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.